AIVITA Biomedical CEO Dr. Hans Keirstead to Deliver Keynote at Advanced Therapies Europe
IRVINE, Calif. – Sep 5, 2023 – AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans S. Keirstead, Ph.D. will participate in a keynote panel at Advanced Therapies Europe, taking place September 5-7 in Estoril, Portugal. In his keynote, Dr. Keirstead will speak about promising future for dendritic cell vaccines in treating cancer and preventing infectious disease, sharing findings from AIVITA’s late-stage clinical trials in cancer and AIVITA’s Safety Net Vaccine Kit that enables vaccine production at point-of-care targeting influenza, malaria, Dengue, and COVID-19. Details are as follows:
Keynote Panel: CAR-T & Beyond: Future of Cell-Based Immunotherapies
Keynote Title: A personal vaccine platform technology for cancer and infectious disease
When: Wednesday, Sep 7, 2023, 15:30 (GMT+1)
Sven Kili, M.D., Principal, Sven Kili Consulting
Evren Alici, M.D., Ph.D., Head of Cell and Gene Therapy Group, Department of Medicine, Karolinska Institutet
Rui A. Sousa, Ph.D., Chief Executive Officer & Chairman, Stemmatters
Hans S. Keirstead, Ph.D., Chairman & Chief Executive Officer, AIVITA Biomedical, Inc.
Marie Csete, M.D., Ph.D., Chief Executive Officer, OkuloVision
Location: Estoril Congress Center, Estoril, Portugal
About AIVITA Biomedical
Founded in 2016 by pioneers in the cell therapy industry, AIVITA Biomedical, Inc. utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline. Our cancer immunotherapy targets the seed of all cancers, tumor-initiating cells, with a unique pan-antigenic approach that targets all neoantigens specific to the patient’s cancer. Our patient-specific cancer treatments have shown great promise including eradicating tumors, without harmful side effects in melanoma, and renal cell cancer, and prolonging progression-free survival in glioblastoma. Our Safety Net Vaccine Kit is targeted to emerging nations enabling point-of-care vaccine production in minimally equipped facilities by minimally trained third-party technicians.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on a number of assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.